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In the developing embryo, the vasculature first takes the form of a web-like network 
called the vascular plexus. Arterial and venous differentiation is subsequently guided by 
the specific expression of genes in the endothelial cells that provide spatial and temporal 
cues for development. Notch1/4, Notch ligand delta-like 4 (Dll4), and Notch downstream 
effectors are typically expressed in arterial cells along with EphrinB2, whereas chicken 
ovalbumin upstream promoter transcription factor II (COUP-TFII) and EphB4 
characterize vein endothelial cells. Hemodynamic forces (blood pressure and blood flow) 
also contribute importantly to vascular remodeling. Early arteriovenous differentiation 
and  local blood flow may hold the key to future inflammatory diseases. Indeed, despite 
the fact that atherosclerosis risk factors such as smoking, hypertension, 
hypercholesterolemia, and diabetes all induce endothelial cell dysfunction throughout the 
vasculature, plaques develop only in arteries, and they localize essentially in vessel 
branch points, curvatures and bifurcations, where blood flow (and consequently shear 
stress) is low or oscillatory. Arterial segments exposed to high blood flow (and high 
laminar shear stress) tend to remain plaque-free. These observations have led many to 
investigate what particular properties of arterial or venous endothelial cells confer 
susceptibility or protection from plaque formation, and how that might interact with a 
particular shear stress environment.  
 
  
Introduction 
Atherosclerosis is a complex chronic disease of the vasculature. Atherosclerotic plaque 
formation is initiated by the accumulation of lipoproteins in the arterial wall which 
trigger a persistent inflammatory response. Locally, endothelial cells (ECs) and vascular 
smooth muscle cells become activated. The ensuing expression of adhesion molecules 
and chemokines stimulates the recruitment of monocytes and T lymphocytes which 
adhere to the endothelium and transmigrate into the underlying intima. The monocyte-
derived macrophages accumulate lipids and become trapped in the form lipid-laden foam 
cells (1, 2). Dendritic cells, originating in arterial intima or derived from monocytes, also 
differentiate into foam cells (3, 4). The resulting accumulation of cells, coupled with 
continuous inflammation, drive the chronic recruitment and activation of leukocytes, 
perpetuating plaque growth and encroachment in the vascular lumen (1, 2, 5). Severe 
vascular narrowing, along with plaque erosion and rupture, are intimately linked to 
clinical events (6). 
It is clear that both a lipid and an inflammation component contribute significantly to the 
progression of atherosclerotic lesions and associated clinical outcomes. On the one hand, 
current and emerging therapeutic agents for this disease are primarily focused on 
modulating lipids, and lipid-lowering statin therapies have proven to be highly effective 
in reducing the cardiovascular events and improving the quality of life for patients with 
coronary heart disease (7). On the other hand, both preclinical and clinical research has 
provided multiple lines of evidence that inflammation and immune responses are integral 
components of the pathogenesis of atherosclerosis (8, 9). Nevertheless, these approaches 
do not address the fundamental question regarding the specificity of atherosclerotic 
plaque localization, which itself may hold clues to how plaque formation may be 
prevented or reversed.  
 
Shear stress and atherosclerosis 
It is well established that atherosclerosis is not distributed evenly in the vasculature. 
Despite the fact that atherosclerosis risk factors such as smoking, hypertension, 
hypercholesterolemia, and diabetes all induce endothelial cell (EC) dysfunction 
throughout the vasculature (10-12), plaques develop essentially in arterial branch points, 
curvatures and bifurcations. These sites are characterized by low, disturbed or oscillating 
blood flow. In comparison, straight segments of arteries, exposed to laminar blood flow, 
remain consistently lesion-free. Differences in shear stress, the frictional force due to 
blood flow, form the basis of these differences in atherosclerosis predilection (13-17). 
Shear stress is sensed essentially by ECs. Slow and oscillatory blood flow induces the 
expression of endothelial adhesion molecules, chemokines, and growth factors that are 
important for leukocyte recruitment and extravasation. Increased activity of the 
proinflammatory transcription factor NFκB by oscillatory flow (18) is likely to contribute 
to these effects. Conversely, high pulsatile shear stress decreases EC turnover and 
promotes anti-oxidative and anti-inflammatory processes. Activation of endothelial NO 
synthase (eNOS) appears to be a key mediator of these atheroprotective effects. NO 
reduces endothelial permeability, migration of leukocytes, and vascular smooth muscle 
cell proliferation while simultaneously promoting EC survival (19, 20). 
 
Arteriovenous identity 
Another particularity of atherosclerosis is that it develops essentially in arteries. Although 
arteriovenous identity is ambiguous in the early embryo, arteries and veins gradually 
differentiate into distinct vessels that have characteristic endothelial cells. EC properties 
were originally believed to derive from the milieu where they evolved, dependent on 
local blood pressure, shear stress, blood oxygenation, or pH (21). However, this notion 
was challenged by the discovery that even before the onset of blood flow, endothelial 
cells express arteriovenous differentiation markers (22, 23). Therefore, although full 
differentiation depends on external cues such as flowing blood, early arterial specification 
occurs intrinsically (24). From hence, it was appreciated that the identity of artery and 
vein endothelium is genetically determined. This did not preclude a potential change in 
EC fate. If for example the local blood flow was reversed in the developing embryo, 
arteriovenous differentiation would similarly be reset according to the new conditions 
(25). Nevertheless, this line of work established a number of genes whose expression 
characterize and, in some cases serve to maintain, arterial and venous identity (26). These 
form a coherent set of interacting molecules (Figure 1). In arteries, high levels of vascular 
endothelial growth factor (VEGF), acting on its co-receptor neuropilin 1 (Nrp1), leads to 
Delta-like 4 (Dll4)-dependent activation of Notch1/4 and downstream expression of hairy 
and enhancer of split (Hes), and hairy and enhancer of split with YRPW motif (Hey1/2). 
In veins, lower levels of VEGF interacting with the Nrp2 co-receptor induce the 
expression of chicken ovalbumin upstream promoter transcription factor II (COUP-TFII), 
which inhibits Notch signaling (27-29). Disparities in Notch signaling also account for 
greater expression of EphrinB2 in arteries, and enhanced expression of its receptor 
EphB4 in veins. Hence, differential expression of Notch ligands, receptors and effectors 
provides temporal and spatial cues critical for embryonic development (30). Furthermore, 
Notch components continue to be expressed across the body in a tissue-dependent 
manner, and Notch signaling continues to play a vital role in regulating differentiation, 
proliferation, and survival in adult tissues including the hematopoietic system (31, 32). 
 
Shear stress and arteriovenous differentiation markers 
In an effort to reconcile shear stress-dependent plaque localization and the arterial-
specific nature of the disease, it is interesting to investigate how these factors interact. 
Although there is consensus on the mechano-sensitivity of arteriovenous differentiation 
markers in general, in vitro experiments have yielded diverse findings, which might 
depend on the type of endothelial cell used or the specific culture conditions.  
Arterial levels of shear stress applied to ECs derived from pluripotent stem cells 
upregulated mRNA levels of Notch1, as well protein-level expression of Notch1 
intracellular domain (NICD)(33). In embryonic stem cells, Notch1 activation and NICD 
translocation were likewise observed within 30 min and augmented with time in response 
to shear stress, increasing EphrinB2 expression dose-dependently (34). In comparison, 
early outgrowth cells (also called endothelial progenitor cells) were more responsive to 
low shear stress (1-5 dynes/cm2), producing increased mRNA levels of Notch1/3, 
Hey1/2, and activin receptor-like kinase 1 (Alk1)(35). Comparable shear stress levels 
were also found to upregulate Notch1 expression in human abdominal aortic endothelial 
cells, whereas higher shear stress levels (≥10 dynes/cm2) did not (36). Notch1 expression 
was required for upregulation of other arterial markers Dll4, Hey1, and Nrp1 by shear 
stress in aortic ECs (36). Similarly, Notch1/4 upregulation was found to precede 
increased Dll1/4, Jagged1, and Hes expression in a rat model of arteriovenous 
malformation, in correlation with increased wall shear stress (37). Shear stress-induced 
arterial specification also required the activation of the Notch pathway through a 
mechanism that involved upregulation of Notch ligands Dll1/4 (38). Interestingly, the 
Notch inhibitor DAPT phenocopied the effects of lowering shear stress on mouse 
embryo, preventing vascular remodeling. The effect of DAPT treatment could be 
partially rescued by injection of starch to increase shear stress levels (39). In a similar 
fashion, optimal Notch1 levels were required for optimal endothelial progenitor cell 
proliferation, migration and adhesion, and consequently re-endothelialization capacity of 
these cells after arterial denudation (40). Collectively, these studies suggest that Notch1 is 
an important regulator of endothelial identity and function, which is preferentially 
induced by low shear stress. Nevertheless, the degree to which cells respond to the shear 
stress stimulus may reflect the development stage of the cells from which ECs are derived 
or the vessels from which they are isolated.  
Results have not been as clear-cut when considering the effects of shear stress on the 
EphrinB2-EphB4 balance. The mRNA levels of the arterial EC marker EphrinB2 
increased in response to low shear stress (1-5 dynes/cm2) in early outgrowth cells, but 
levels of the venous endothelial cell markers EphB4 and Nrp2 decreased (35). The same 
expression pattern was observed in embryonic stem cells (34). In response to arterial 
shear stress, early outgrowth cell expression of EphrinB2 also augmented, but EphB4 
remained unchanged (41). Likewise, arterial levels of shear stress were found to 
upregulate mRNA levels of EphrinB2, when applied to ECs derived from pluripotent 
stem cells (33). However, another study found that EphrinB2 expression was enhanced in 
ECs exposed to oscillatory flow rather than laminar flow (42). Furthermore, arterial shear 
stress downregulated EphrinB2 mRNA in coronary endothelial cells and umbilical vein 
endothelial cells, but conditions mimicking either venous or arterial shear stress did not 
affect EphB4 expression (43). Finally, in isolated perfused veins, the opposite was 
observed. Levels of EphrinB2 were unaffected by arterial shear stress, whereas EphB4 
was decreased under such flow (44). Hence, although there is some discrepancy 
regarding the extent to which EphrinB2/EphB4 are affected by shear stress, there is a 
trend towards upregulation of EphrinB2 in cells exposed to shear stress, whereas EphB4 
tends to remain unchanged or is reduced in such conditions.  
 
Atherosclerosis and arteriovenous differentiation markers 
It is interesting to note the loss of venous identity without gain of arterial identity in veins 
exposed to arterial magnitudes of shear stress ex vivo (44). There was even a loss of 
EphB4 in vein grafts placed in the arterial circulation in vivo (45, 46). Since vein grafts 
used as coronary artery bypass can develop atherosclerosis (47), these observations 
suggest that venous identity is protective rather than arterial identity harmful. In the 
setting of venous bypass grafts, it is important to remember that imposing arterial blood 
pressure produces a high tensile stress that could itself instigate pro-inflammatory 
processes consistent with atherosclerosis formation (48). Moreover, the vein diameter 
increases in this context, lowering shear stress; placing a reinforcing mesh around a vein 
graft in bypass conditions lowers remodeling and maintains high shear stress (49). 
Nevertheless, venous ECs were found to be less thrombogenic than arterial ECs (50). 
Moreover, COUP-TFII knockdown in venous ECs resulted in the expression of Notch1 
and Jagged1, which are normally expressed only in arterial ECs. This led to enhanced 
expression of atherogenic genes after stimulation with angiotensin II, and increased 
angiotensin-induced cell adhesion (51). Interestingly, endothelial expression of the 
angiotensin II AT1 receptor is shear stress-sensitive and expressed essentially in athero-
prone arterial sites (52). Inversely, attenuation of Notch1 signaling by application of 
soluble jagged1 (53) or by Notch1 inhibition with DAPT (54) suppressed intimal 
hyperplasia in a model of rat vein graft. In summary, there is evidence vein graft disease, 
which occurs when veins are transposed in an arterial context, may be attenuated by 
modulating arteriovenous differentiation in the favor of venous markers. 
Although vein grafts can develop atherosclerosis, the disease is primarily found in 
arteries, at sites of predilection determined by the shear stress environment (Figure 2). A 
comparison of patient atherosclerotic arteries with healthy controls revealed aberrantly 
low methylation of Notch1 in diseased vessels, and an accompanying increased Notch1 
expression (55). Another study noted increased expression of Notch1/4 and Hey1 at 
atherosclerotic sites of both human and mouse aortas (56). In mice, no differences in the 
expression of EphrinB2 mRNA were detected between the plaque-prone inner curvature 
and athero-protected outer curvature of the aorta. However, endothelial staining for 
EphrinB2 was detected in the inner aortic curvature but not in the outer curvature (42). 
Strong expression of Notch1 and Hes1 was also noted in aortas of hypercholesterolemic 
apolipoprotein E (ApoE)-/- mice, compared with wild-type controls, being particularly 
abundant in plaque macrophages. Fittingly, treatment of with a Notch1 inhibitor reduced 
plaque size and lowered macrophage infiltration in these mice (57). Along the same lines, 
administration of a Dll4 neutralizing antibody reduced NFκB activity, decreased 
macrophage accumulation, and abated the development of atherosclerosis in low density 
lipoprotein receptor (LDLR)-/- mice (58).  
Atherosclerosis predisposes to formation of aneurysm both in patients and in mice. 
Accordingly, activation of Notch1 signaling was observed in the aortic aneurysmal tissue 
of ApoE-/- mice, and a similar activation of Notch1 was observed in aneurysms of 
humans undergoing abdominal aortic aneurysms (AAA) repair (59). Notch1 
haploinsufficiency or pharmacological inhibition of Notch1 significantly reduced the 
occurrence of AAA in response to angiotensin II in ApoE-/- mice (59). These findings 
were confirmed in a second study showing that inhibition of Notch1 signaling reduces 
macrophage accumulation and AAA formation in mice (60). Interestingly, Notch 
intracellular domain (NICD) and Hes1 were detected predominantly in aneurysmal 
fibroblasts and macrophages (61), suggesting that Notch1 signaling in inflammatory cells 
contributes importantly to progression of the disease. This concept also held in a wound 
healing model mice, where myeloid-specific Notch1 deletion decreased tumor necrosis 
factor (TNF)-α expression and macrophage recruitment (62). Finally, flow cytometry and 
immunohistochemistry demonstrated that Notch1 haploinsufficiency prevented the influx 
of inflammatory macrophages at the aneurysmal site by causing defects in macrophage 
migration and proliferation (59). Hence expression of Notch1 in leukocytes is paramount 
to the normal function and the inflammatory response in these cells.  
In fact, Notch1 signaling is both activated by and stimulator of inflammatory signals. For 
the most part, these processes have been studied in macrophages, a predominant cell type 
in atherosclerotic plaques. Macrophage function is strongly influenced by exposure to 
cytokines; this polarization process generates two macrophage subtypes broadly referred 
to as M1 and M2. M1 “classically activated” macrophages are induced by interferon 
(IFNγ) and drive pro-inflammatory responses (63, 64). M2 ”alternatively activated” 
macrophages differentiate in the presence of interleukin (IL)-10, IL-4 or IL-13 and 
express anti-inflammatory mediators (65), associated with wound healing. The 
progression and exacerbation of atherosclerosis are propelled by gradual lesional 
accumulation of M1 macrophages which secrete pro-inflammatory cytokines (66). 
Conversely, the clearance of apoptotic cells by phagocytosis and plaque regression are 
associated with M2 macrophage function (67, 68). Notch1 expression is enhanced during 
cellular stress in macrophages, and Notch1 inhibition reduces inflammatory cytokine 
secretion and promotes the M2 macrophage phenotype in these conditions (69). In 
agreement, Dll4 skews macrophages towards an M1 phenotype  (58). In LDLR-/- mice, 
administration of a Dll4-blocking antibody suppressed macrophage M1 pro-inflammatory 
gene expression, prevented vein graft macrophage accumulation, and diminished lesion 
development (70). 
Beyond M1/M2 conversion, Notch1 has been found to influence macrophage response to 
toll-like receptor (TLR) agonists such as bacterial lipopeptide, polyI:C, 
lipopolysaccharide (LPS) and unmethylated CpG DNA. These agonists all induced up-
regulation of Notch1 in primary and macrophage-like cell lines (71). Moreover, Notch 
and TLR pathways cooperated to activate Notch target genes, including Hes1 and Hey1, 
and to increase production of canonical TLR-induced cytokines TNF, IL-6, and IL-12 
(72). In fact, Notch signaling was found to increase both basal and LPS-induced NFκB 
activation, favoring the expression these cytokines (73). In return, inhibition of Notch 
signaling decreased induction of the inflammatory cytokines in macrophages stimulated 
with LPS (62, 71). Additionally, macrophages from Notch1 (+/-) mice demonstrated 
decreased induction of IL-6, IL-12, and TNF-α in response to LPS, compared with wild-
type mice (62). Although LPS was an efficient stimulator of Notch1, Dll4 was the most 
effective ligand to induce Notch activation and increase NFκB transcriptional activity in 
macrophages (73). Keeping the context of atherosclerosis in mind, it is interesting to note 
that not only LPS, but also low density lipoproteins can enhance Dll4 expression in 
macrophages (74). Finally, although there is a preponderance of experiments 
investigating pro-inflammatory effects of Notch1 in leukocytes, it is clear that other cells 
within the plaque have influence on or are impacted by Notch signaling. For example, 
smooth muscle cells were found to highly express Jagged1, which subsequently activated 
Notch1 in the transmigrated endothelial progenitors to promote their differentiation into 
macrophages (75). More importantly, when considering the shear stress-specific 
localization of atherosclerotic plaques and shear-dependent Notch1 regulation, Notch1 
activation inhibited EC growth and increased EC senescence, and it enhanced leukocyte 
transendothelial migration in vitro, at least in part through IL-6 (76). 
Despite the fact that the majority of studies report a benefit of Notch1 inhibition in 
reducing inflammatory, there is some evidence to the contrary. In ECs derived from stem 
cells, it was revealed that Notch1 expression is necessary for the activation of anti-
inflammatory networks by shear stress (77). In agreement, expression of the Notch1 
inhibitor delta-like 1 homolog (Dlk1) was accentuated in response to reduced flow and 
coincided with poor EC turnover and enhanced atherosclerosis (78). Endothelial Notch1 
haploinsufficiency was also found to enhance leukocyte adhesion and atherosclerotic 
lesions in mice (79), suggesting that an optimal expression of Notch1 may be necessary 
for ideal EC function. In cultured human monocytes, Dll4 induced the transcription of 
Notch target gene Hes1 and inhibited the basal and TNF-α-stimulated production of IL-8 
(80). Furthermore, compared to LPS alone, simultaneous stimulation of dendritic cells 
with Jagged1 fusion protein and LPS resulted in significantly enhanced expression of the 
anti-inflammatory cytokine IL-10, whilst secretion of pro-inflammatory IL-12 was 
significantly inhibited (81). Finally, LPS was found to inhibit Notch1 intracellular 
domain transcription activity (82). Activation of a Hes1- and Hey1-mediated inhibitory 
feedback loop could very well account for some protective effects of Notch1 (72). 
Moreover, both pro- and anti-inflammatory cytokines were shown to alter Notch 
expression levels or elicit a switch in Notch expression, with corresponding impact on EC 
function (83, 84). Further work will be needed to more precisely define which Notch 
ligands and isoforms contribute to inflammation, and how this might be influenced by the 
pathophysiological setting. 
 
To further complicate matters, EphrinB2/EphB4 differention markers also play a role in 
the inflammatory response. In principle, Eph receptors are activated by membrane-bound 
Ephrins, such that direct cell-to-cell contact is required for receptor activation. Moreover, 
Ephrin-Eph binding triggers signaling in both the ligand-bearing and the receptor-bearing 
cell. This bi-directional signaling tends to result in the repulsion of the cells involved. 
Hence, Ephrin-Eph interaction between ECs and leukocytes would tend to limit their 
interaction. Conversely, decreased expression of Ephrin receptors in inflamed vasculature 
would promote leukocyte adhesion (85). Human CD4+ T cells and polymorphonuclear 
cells demonstrated increased expression of EphrinB2 mRNA in response to TNFα (86). 
In addition, monocytes were found to express EphB2, one of the possible receptors for 
EphrinB2, and the expression of EphB2 in monocytes was increased upon their adhesion 
(87). These observation would suggest that Ephrin-Eph expression would limit 
interaction between leukocytes. High EphB2 in monocytes could also explain their lower 
adhesion to ECs exposed to shear stress, since these conditions tend to increase 
EphrineB2 expression, as noted above. Nevertheless, the activation of EphrinB ligands 
was found to lower the integrity of EC junctions and enhance the pro-inflammatory 
phenotype of the endothelium, facilitating the through of extravasation of EphB2 positive 
leukocytes (88).  
 
  
Conclusion 
Atherosclerotic plaque localization is generally restricted to arterial segments that are 
exposed to low or oscillatory shear stress. Because endothelial cells are the primary 
sensors of shear stress, it stands to reason that they hold a key to the processes that allow 
for local plaque development. Even in the developing embryo, arterial endothelial cells 
express specific differentiation markers that may hold the key to understanding why this 
vasculature is uniquely susceptible to plaque formation. There is accumulating evidence 
that Notch1 may be a promising target in the fight against this disease, both because 
Notch1 tends to amplify inflammatory signaling and because there is evidence that at 
least in some contexts, endothelial Notch1 expression is enhanced by low shear stress 
typical of athero-prone sites. Nevertheless, it appears that an optimal levels of Notch1 are 
required for proper endothelial cell function, such that specific targeting of macrophage 
Notch1 may prove to be the better therapeutic choice. As regards the EphrinB2-EphB4 
balance, adequate expression of the arterial marker may be protective, but only to a 
certain extent. As is the case with Notch1, EphrinB2 overexpression may tip ECs towards 
a pro-inflammatory phenotype. Finally, although little studied, it appears that the 
expression of the venous marker COUP-TFII protects vessels from inflammatory cell 
infiltration.  
 
  
Figure 1. Signaling pathways involved in arteriovenous differentiation. 
 In arteries, high VEGF levels acting on the NRP1 co-receptor activate the Dll4/Notch 
pathway, leading to activation of Hey and Hes1/2. This pathway is further induced by 
Wnt signaling. As a result, EphrinB2 expression is enhanced whereas EpbB4 and COUP-
TFII are repressed. In veins, lower VEGF levels acting on the NRP2 co-receptor produce 
an abated Dll4/Notch response, lifting the repression of EphB4 and COUP-TFII. Brahma-
related gene 1 (BRG1) contributes to COUP-TFII activation.  
 
Figure 2. Interaction between shear stress, arteriovenous differentiation markers, 
and cells that make up the atherosclerotic plaque.  
A. The distribution of atherosclerotic lesions (yellow) within arteries follows a distinct 
pattern based on local blood flow. B. Arterial sections exposed to high laminar shear 
stress, such as the outer wall of the aortic arch, are typically devoid of plaques. 
Endothelial cells (EC) in such regions express optimal levels of Notch1, which are 
associated with pro-survival and anti-inflammatory responses. Moreover, overexpression 
of EphrinB2 in ECs exposed to high shear stress acts as a repellent for monocytes that 
express EphB2. C. Plaques typically form in regions where blood flow is low or 
oscillatory, such as the inner curvature of the aortic arch. ECs exposed to low flow tend 
to express high levels of Notch1 and EphrinB2, which induce endothelial dysfunction and 
leukocyte extravasation. In the plaque, oxidized LDL accumulation and subsequent 
chemokine release further stimulate monocyte influx and induce Notch1 expression 
macrophages. This skews macrophages towards the pro-inflammatory M1 type, and 
further stimulates pro-inflammatory signaling (NFκB) and cytokine production. On the 
contrary, if Notch1 is inhibited in this context, M2 macrophages arise and anti-
inflammatory cytokines are expressed. 
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